Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 10, 2013, Pages 1302-1309

  Graves, Jennifer ^a,b   Galetta, Steven L ^a   Palmer, Jeffrey ^c   Margolin, David H ^c   Rizzo, Marco ^c   Bilbruck, John ^d   Balcer, Laura J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENZYME CORPORATION   (United States)

^d UBC Envision Group   (United Kingdom)

Author keywords

alemtuzumab; contrast sensitivity; disease modifying therapy; interferon beta; Multiple sclerosis; outcome measurements; relapsing remitting multiple sclerosis; visual function

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON;

ADULT; ARTICLE; CONTRAST SENSITIVITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; EUROPE; EXPLORATORY RESEARCH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; UNIVERSITY HOSPITAL; VISION; VISUAL ACUITY CHART;

ALEMTUZUMAB; CONTRAST SENSITIVITY; DISEASE MODIFYING THERAPY; INTERFERON BETA; MULTIPLE SCLEROSIS; OUTCOME MEASUREMENTS; RELAPSING-REMITTING MULTIPLE SCLEROSIS; VISUAL FUNCTION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CONTRAST SENSITIVITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SINGLE-BLIND METHOD; VISION DISORDERS;

EID: 84883337717     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513475722     Document Type: Article

References (34)

1. Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005 ; 4: 111-121
2. McDonald WI, Barnes D. The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system. J Neurol Neurosurg Psych. 1992 ; 55: 747-752
3. Newman NJ Walsh and Hoyt's clinical neuro-opthalmology. 1998: 5th edition; pages 5539-5676. Miller NR Newman NJ, ed. Baltimore: Williams & Wilkins ; 1998: 5539-5676.
4. Sisto D, Trojano M, Vetrugno M, et al. Subclinical visual involvement in multiple sclerosis: A study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. Invest Ophthalmol Vis Sci. 2005 ; 46: 1264-1268
5. Lycke J, Tollesson PO, Frisén L. Asymptomatic visual loss in multiple sclerosis. J Neurol. 2001 ; 248: 1079-1086
6. Engell T, Trojaborg W, Raun NE. Subclinical optic neuropathy in multiple sclerosis. A neuro-ophthalmological investigation by means of visually evoked response, Farnworth-Munsell 100 Hue test and Ishihara test and their diagnostic value. Acta Ophthalmol (Copenh). 1987 ; 65: 735-740
7. Balcer LJ, Frohman EM. Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity. Neurology. 2010 ; 74: S16-23
8. Balcer LJ, Baier ML, Pelak VS, et al. New low-contrast vision charts: Reliability and test characteristics in patients with multiple sclerosis. Mult Scler. 2000 ; 6: 163-171
9. Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. Clin Vision Sci. 1988 ; 2: 187-199
10. Regan D, Neima A. Low-contrast letter charts as a test of visual function. Ophthalmol. 1983 ; 90: 1192-1200
11. Kupersmith MJ, Nelson JI, Seiple WH, et al. The 20/20 eye in multiple sclerosis. Neurology. 1983 ; 33: 1015-1020
12. Nordmann JP, Saraux H, Roullet E. Contrast sensitivity in multiple sclerosis: A study in 35 patients with and without optic neuritis. Ophthalmologica. 1987 ; 195: 199-204
13. Trobe JD, Beck RW, Moke PS, et al. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. Am J Ophthalmol. 1996 ; 121: 547-553
14. Wu GF, Schwartz ED, Lei T, et al. Relation of vision to global and regional brain MRI in multiple sclerosis. Neurology. 2007 ; 69: 2128-2135
15. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmol. 2006 ; 113: 324-332
16. Osborne B, Jacobs D, Markowitz C, et al. Relation of macular volume to retinal nerve fiber layer thickness and visual function in multiple sclerosis. Neurology. 2006 ; 66: A14
17. Balcer LJ, Baier ML, Cohen JA, et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology. 2003 ; 61: 1367-1373
18. Coles A, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J Neurol. 2006 ; 253: 98-108
19. Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008 ; 359: 1786-1801
20. Fox EJ, Sullivan HC, Gazda SK, et al. A single-arm, open-label study of alemtuzumab in treatment refractory patients with multiple sclerosis. Eur J Neurol. 2012 ; 19: 307-311
21. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
23. Elliott DB, Sanderson K, Conkey A. The reliability of the Pelli-Robson contrast sensitivity chart. Ophthalmic Physiol Opt. 1990 ; 10: 21-24
24. Ying Z, Wei LJ. The Kaplan-Meier estimate for dependent failure time observations. J Multivar Anal. 1994 ; 50: 17-29
25. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 2001 ; 11: 9-21
26. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: Post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011 ; 10: 338-348
27. McGwin G, Chapman V, Owsley C, et al. Visual risk factors for driving difficulty among older drivers. Accid Anal Prev. 2000 ; 32: 735-744
28. Owsley C, Stalvey BT, Wells J, et al. Visual risk factors for crash involvement in older drivers with cataract. Arch Ophthalmol. 2001 ; 119: 881-887
29. Lord S, Dayhew J. Visual risk factors for falls in older people. J Am Geriatr Soc. 2001 ; 49: 508-515
30. Lord SR, Menz HB. Visual contributions to postural stability in older adults. Gerontology. 2000 ; 46: 306-310
31. Ma SL, Shea JA, Galetta SL, et al. Self-reported visual dysfunction in multiple sclerosis: New data from the VFQ-25 and development of an MS-specific vision questionnaire. Am J Ophthalmol. 2002 ; 133: 686-692
32. Weinstock-Guttman B, Baier M, Stockton R, et al. Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis. Mult Scler. 2003 ; 9: 529-534
33. Baier ML, Cutter GR, Rudick RA, et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology. 2005 ; 64: 992-995
34. Balcer LJ, Galetta SL, Calabresi PA, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007 ; 68: 1299-1304